Acadia Pharmaceuticals ACAD EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Acadia Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Acadia Pharmaceuticals's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Acadia Pharmaceuticals's EBITDA margin?
- Acadia Pharmaceuticals (ACAD) reported EBITDA margin of 8.5% in Q1 2026.
- How has Acadia Pharmaceuticals's EBITDA margin changed year-over-year?
- Acadia Pharmaceuticals's EBITDA margin decreased by 66.0% year-over-year, from 24.9% to 8.5%.
- What is the long-term trend for Acadia Pharmaceuticals's EBITDA margin?
- Over 4 years (2020 to 2025), Acadia Pharmaceuticals's EBITDA margin has grown at a -35.8% compound annual growth rate (CAGR), from -64.2% to 10.9%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.